Skip to main content

The Neurelis Board of Directors are
Dedicated to Achieving Progress

Our board of directors have the relevant experience needed to help a specialty pharmaceutical company thrive.

Craig C. Chambliss 

President and CEO/Co-Founder

C raig Chambliss has 25 years invested in the pharmaceutical, biotechnology, and drug delivery arenas, with primary focus on diseases of the central nervous system (CNS) and epilepsy, in particular. He co-founded Neurelis in 2007 and has served as CEO and President since 2013.
In 2010, Mr. Chambliss joined NextWave Pharmaceuticals as Chief Business Officer and directed the corporate refocus to the CNS market, raising $45M in Series C financing and culminating in the sale of NextWave to Pfizer for over $700M in 2012. Prior to NextWave and Neurelis, he led commercial operations at Questcor Pharmaceuticals, from 2005-2007, where he was responsible for helping to engineer the transition to a CNS-focused company and establish the commercial infrastructure to support the relaunch of Acthar® Gel (repository corticotropin injection).
Mr. Chambliss began his career in pharmaceutical sales at Bristol-Myers Squibb and joined Alza Pharmaceuticals upon the launch of their commercial organization in 1994. While at Alza Pharmaceuticals, he served in various sales and marketing roles prior to joining Elan Pharmaceuticals where he served as Director of Business Development for CNS assets. In 2001, along with other former Dura and Elan executives, Mr. Chambliss launched Xcel Pharmaceuticals, a CNS start-up focused on epilepsy and, primarily, the treatment of acute repetitive seizures. He led commercial operations and the successful launch of Diastat® (diazepam rectal gel) until Xcel's acquisition by Valeant Pharmaceuticals in 2005 for $280M. Mr. Chambliss holds a BS in Finance and a BS in Accounting from Missouri State University.


Dr. Priyanka Belawat 


D r. Priyanka Belawat is an Investment Advisor for HBM Healthcare Investments.  Dr. Belawat has 10 years of experience in venture and private equity investing in the healthcare space. She has been instrumental in many portfolio investments of HBM funds in areas of biotech, pharma diagnostics and services. Presently, she represents HBM funds on the board of Neurelis Inc., and is board observer to ARMO Biosciences (USA, Immuno-oncology), TrueNorth Therapeutics (USA, Rare diseases), SAI Lifesciences (India, Contract research and manufacturing), and 1MG (India, Online pharma portal). She was closely involved with HBM’s investment in Advanced Accelerator Applications (NASDAQ:AAAP), a French company in the radio-therapeutics and radio-diagnostics space, which went public at US NASDAQ in 2014. She also has extensive knowledge of the Indian pharma sector and has been involved in various public equity, fund, and direct private investments in India.
Dr. Belawat holds a doctorate in molecular biology and genetics from the University of Zurich and completed post-doctorate work at HKUST.

Cam L. Garner


C am Garner has co-founded specialty pharmaceutical companies Zogenix, Inc., Evoke Pharma, Cadence Pharmaceuticals, Inc., Somaxon Pharmaceuticals, Inc., Elevation Pharmaceuticals, Inc., DJ Pharma, Verus Pharmaceuticals, Inc., Xcel Pharmaceuticals, Inc., Meritage Pharma, Inc., Kalyra Pharmaceuticals, Inc., and OrPro Therapeutics, Inc.
Mr. Garner currently serves as Chairman of Zogenix, Evoke, and OrPro Therapeutics and as Executive Chairman of Kalyra Pharmaceuticals. He served as Chairman of Xcel Pharmaceuticals until it was acquired in March 2005 by Valeant Pharmaceuticals International, DJ Pharma until it was sold to Biovail in 2000, Elevation Pharmaceuticals until it was acquired by Sunovion Pharmaceuticals Inc. in September 2012, Cadence Pharmaceuticals until it was acquired by Mallinckrodt plc in March 2014, and Meritage Pharma until it was acquired by Shire plc in February 2015.
Mr. Garner was Chief Executive Officer of Dura Pharmaceuticals, Inc. from 1989 to 1995 and its Chairman and Chief Executive Officer from 1995 until it was sold to Elan in November 2000. He also serves on the board of directors of Aegis Therapeutics, Inc. He earned his BA in Biology from Virginia Wesleyan College and an MBA from Baldwin-Wallace College.

David F. Hale


D avid Hale is a co-founder and Director of Neurelis.  He is Chairman and CEO of Hale BioPharma Ventures, LLC, a private company focused on the formation and development of biotechnology, specialty pharma, diagnostic, and medical device companies. He also serves as Chairman of 2 public companiesBiocept, Inc., a cancer diagnostic company, and Conatus Pharmaceuticals, Inc., a liver disease companyand is on the board of Cassiopea, a dermatology company. He served as Chairman of Santarus, Inc., prior to its sale to Salix Pharmaceuticals, Inc. in 2014; SkinMedica, Inc., prior to its sale to Allergan in 2012; Micromet, Inc., prior to its sale to Amgen Inc. in 2012; Somaxon Pharmaceuticals prior to its sale to Pernix in 2013; and Crisi Medical Systems prior to its sale to Becton-Dickinson in 2015.
Mr. Hale is a serial entrepreneur who has been involved in the formation and development of a number of biomedical companies. He is a co-founder and Chairman of Advantar Laboratories, Inc., Agility Clinical, Inc., MDRejuvena, Inc., Skylit, Inc., Recros Medica, and a co-founder and Managing Member of Dermata Therapeutics, LLC. He is also Chairman of Colorescience, Inc., and Ridge Diagnostics, Inc. He was also a co-founder of Cadence, Evoke, Elevation, and Zogenix. 
In 1982, after joining Hybritech, Inc., the first monoclonal antibody company, Mr. Hale served as COO and President, and then Chief Executive Officer when Hybritech was acquired by Eli Lilly and Co. in 1986. From 1987 to 1997 he was Chairman, President, and CEO of Gensia, Inc., which merged with SICOR to become Gensia Sicor, Inc., and was then acquired by Teva Pharmaceuticals. He was a co-founder and Chairman of Viagene, Inc. from 1987 to 1995, when Viagene was acquired by Chiron, Inc.  In 1997, he was a co-founder and served as Chairman of LMA North America until its merger with LMA International in 2004. He was President and CEO of Women First HealthCare, Inc., from late 1997 to June 2000, prior to joining CancerVax in October 2000, where he served as President and CEO from 2000 until its merger with Micromet, Inc. in 2006, when he became Chairman. 
Prior to joining Hybritech, Mr. Hale was Vice President and General Manager of BBL Microbiology Systems, a division of Becton, Dickinson & Co. from 1971 to 1980, and held various marketing and sales management positions with Ortho Pharmaceutical Corporation, a division of Johnson & Johnson, Inc.

Kevin Li, PhD

Chairman of the Board of Directors

D r. Kevin Li is a Managing Partner at LYZZ Capital, with more than 15 years of professional experience in biomedical sciences, healthcare investment, and entrepreneurship. He has been a Partner at DT Capital heading up healthcare investments since 2011.
Previously, Dr. Li was the Chief Scientific Officer of China Nuokang Biopharma, a leading biopharmaceutical company in China, from 2009-2011, and a Partner at HBM BioMed China, a Shanghai-based venture capital fund affiliated with the HBM Bioventures 2007-2009. Prior to HBM, he was a co-founder of Fountain Medical Development, a leading clinical contract research organization in Asia serving international clients, and an investment manager at Toucan Capital, a venture capital fund focused on biotech investments in the United States.
Dr. Li was a Damon Runyon-Walter Winchell Fellow at Stanford University from 1997 to 2000 and received his PhD in biological sciences from Indiana University in 1997. He has been an investor and board member of a number of biomedical companies in China, including Xili Pharma, Wuhan Hiteck Biopharma, Chipscreen, China Nuokang, Wuxi Royal, and Fountain Medical.

Eric Zhang, MD


D r. Eric Zhang is a Managing Partner at LYZZ Capital.  Dr. Zhang was trained as an endocrinologist at the Rui Jin Hospital in Shanghai and earned his EMBA from the China Europe International Business School (CEIBS). He has more than 15 years of pharmaceutical marketing and sales experience with multinational companies, hands-on operational and management experience, and an extensive network in the pharmaceutical business in China.
Dr. Zhang was with Roche for more than 10 years from 1998 until 2008. While at Roche, he oversaw the marketing and sales of all pharmaceutical products, with over 1,000 sales reps and 3B RMB in revenue. He was involved in the launch of multiple blockbuster products, including PEGASYS, Herceptin, Avastin, MabThera, XELODA, and Tamiflu. After Roche, he co-founded Suzhou Biovention, a stent company, and then was COO of Eddingpharm.
Before co-founding LYZZ Capital, Dr. Zhang was a Venture Partner at DT Capital and General Manager of Jianxin Venture Healthcare Fund, with 300M RMB under management, where he led investments in Shenzhen Chipscreen, MeeHealth, and Techfields.

All trademarks are the property of their respective owners.